Overview

Webcast ImageWebcast
Audentes Therapeutics at the Bank of America Merrill Lynch Health Care Conference (Replay)
05/16/18 at 11:20 a.m. PT
Audentes Therapeutics at the Bank of America Merrill Lynch Health Care Conference
Wednesday, May 16, 2018 11:20 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$38.24
Change (%) Stock is Down 3.15 (0.00%)
Volume1,113,096
Data as of 05/18/18 4:00 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $38.24 with a 52 week high of $42.61 and a 52 week low of $13.90.
Recent NewsMore >>
05/16/18
Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
05/09/18
Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
05/09/18
Audentes Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Andrew H. Chang
Director, Investor Relations
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.